A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...
A targeted radiation drug being developed by Indianapolis-based Point BioPharma met its goal in a late-stage prostate cancer study, but fell short of analyst expectations for a greater treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback